Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells

BMC Cancer

Volumn 4, Issue , 2004, Pages

  Celano, Marilena ^a   Calvagno, Maria Grazia ^a   Bulotta, Stefania ^a   Paolino, Donatella ^a,b   Arturi, Franco ^a   Rotiroti, Domenicoantonio ^a   Filetti, Sebastiano ^c   Fresta, Massimo ^a   Russo, Diego ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; GEMCITABINE; LIPOSOME; TRYPAN BLUE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG CARRIER; DRUG DERIVATIVE;

ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CONTENT; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; FLUOROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MORTALITY; THYROID CARCINOMA; TUMOR CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; PATHOLOGY; THYROID TUMOR; TUMOR CELL CULTURE;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DEOXYCYTIDINE; DRUG CARRIERS; HUMANS; LIPOSOMES; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 13144291647     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-4-63      Document Type: Article

References (23)

1. Ain KB: Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998, 8:715-726.
2. Pasieka JL: Anaplastic thyroid cancer. Curr Opin Oncol 2003, 15:78-83.
3. Abratt RP: Gemcitabine hydrochloride: combination of activity and tolerability (Summary). Anticancer Drugs 1995, 6:63-64.
4. Haller DG: Chemotherapy for advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003, 56(4 Suppl):16-23.
5. Fowler WC Jr, Van Le L: Gemcitabine as a single-agent treatment for ovarian cancer. Gynecol Oncol 2003, 90: 21-23.
6. Harper P: Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer. Semin Oncol 2003, 30(4 Suppl 10):2-12.
7. Lawrence TS: Radiation sensitizers and targeted therapies. Oncology (Huntingt) 2003, 17(12 Suppl 13):23-28.
8. Ringel MD, Greenberg M, Chen X, Hayre N, Suzuki K, Priebat D, Saji M, Burman KD: Cytotoxic activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) in poorly differentiated thyroid carcinoma cells. Thyroid 2000, 10:865-869.
9. Delord JP, Raymond E, Chaouche M, Ruffie P, Ducreux M, Faivre S, Boige V, Le Chevalier T, Rixe O, Baudin E, Pautier P, Rodier JM, Chouaki N, Escudier B, Kayitalire L, Armand JP: A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies. Ann Oncol 2000, 11:73-79.
10. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK: Maximum-tolerated dose defined for single-agent gemcitabine. A phase I dose-escalation study in chemotherapy-naïve patients with advanced non-small-cell lung cancer. J Clin Oncol 1997, 15:310-316.
11. Fresta M, Panico AM, Bucolo C, Giannavola C, Puglisi G: Characterization and in-vivo ocular absorption of liposome-encapsulated acyclovir. J Pharm Pharmacol 1999, 51:565-576.
12. Fresta M, Puglisi G: Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes. Pharm Res 1999, 16:1843-1849.
13. Russo D, Arturi F, Bulotta S, Pellizzari L, Filetti S, Manzini G, Damante G, Tell G: Ape1/ref-1 expression and cellular localization in human thyroid carcinoma cell lines. J Endocrinol Invest 2001, 24:RC10-12.
14. Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LN: Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J Control Rel 2003, 92: 65-273.
15. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M: Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 1999, 141: 43-457.
16. Spitzweg C, Morris JC: The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol 2002, 57:559-574.
17. Nagayama Y, Yokoi H, Takeda K, Hasegawa M, Nishihara E, Namba H, Yamashita S, Niwa M: Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 2000, 85:4081-4086.
18. Takeda T, Inaba H, Yamazaki M, Kyo S, Miyamoto T, Suzuki S, Ehara T, Kakizawa T, Hara M, DeGroot LJ, Hashizume K: Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter. J Clin Endocrinol Metab 2003, 88:3531-3538.
19. To H, Ohdo S, Shin M, Uchimaru H, Yukawa E, Higuchi S, Fujimura A, Kobayashi E: Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats. J Pharm Pharmacol 2003, 55:803-810.
20. Allen TM: Liposomes. Opportunities in drug delivery. Drugs 1997, 54:8-14.
21. Gebbia V, Mauceri G, Fallica G, Borsellino N, Tirrito ML, Testa A, Varvara F, Colombo A, Ferrera P: Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. Oncology 2002, 63:23-30.
22. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK: Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998, 95:4607-4612.
23. Voskoglou-Nomikos T, Pater JL, Seymour L: Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003, 9: 227-4239.